...
机译:躁郁症I型患者的维持治疗:奎硫平与锂或Divalproex联合使用的一项北美研究结果(试验127)
Trisha Suppes, M. D., Ph.D.Eduard Vieta, M.D., Ph.D.Sherry Liu, Ph.D.Martin Brecher, M. D.Björn Paulsson, M. D.Trial 127 InvestigatorsPresented in part in poster format at the 46th annual meeting of the American College of Neuropsychopharmacology, Boca Raton, Fla., December 2007, the third Biennial Conference of the International Society for Bipolar Disorders, Delhi, India, January 2008, the European Congress of Psychiatry, Nice, France, April 2008, the International Review of Bipolar Disorders, Copenhagen, April 2008, the Society of Biological Psychiatry, Washington, D.C., May 2008, the Collegium Internationale Neuro-Psychopharmacologicum, Munich, July 2008, and the International Forum on Mood and Anxiety Disorders, Vienna, November 2008. Received Feb. 6, 2008, revisions received April 24 and Dec. 1, 2008, accepted Dec. 4, 2008 (doi: 10.1176/ appi.ajp.2008.08020189). From the Department of Psychiatry and Behavioral Sciences, Stanford Medical Center and VA Palo Alto Health Care System, Palo Alto, Calif., Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Spain, McLean Hospital, Harvard Medical School, Boston, AstraZeneca Pharmaceuticals LP, Wilmington, Del., and AstraZeneca Pharmaceutical, Södertälje, Sweden. Address correspondence and reprint requests to Dr. Suppes, 3801 Miranda Ave. (151 T), Palo Alto, CA 94304, tsuppes@stanford.edu (e-mail).In the past 12 months, Dr. Suppes has received research funding or medication support from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, JDS Pharmaceuticals, NIMH, Novartis, Pfizer, and the Stanley Medical Research Institute, has served in a consulting or advisory capacity to Orexigen Therapeutics, and has received royalties from Compact Clinicals, in the past 36 months, she additionally received research funding or medication support from Janssen Pharmaceutica and Wyeth, served in a consulting or advisory capacity to Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly Research Laboratories, GlaxoSmithKline, JDS Pharmaceuticals, Janssen Pharmaceutica, Novartis, Ortho-McNeil, Pfizer, Shire, Solvay, and UCB Pharma, and served on speakers bureaus for AstraZeneca and GlaxoSmithKline. Dr. Vieta has served as a consultant to AstraZeneca, Bial, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Merck Sharp & Dohme, Novartis, Organon, Pfizer, Sanofi, Servier, and UCB, has received research grants from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Novartis, and Pfizer, and is a speaker for or serves on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Organon, Pfizer, Sanofi, and Servier. Dr. Paulsson and Dr. Liu are employees of AstraZeneca Pharmaceuticals LP. Dr. Brecher is a former employee of AstraZeneca.Supported by AstraZeneca Pharmaceuticals (study D1447C00127).The authors thank Dr. Eleanor Bull from PAREXEL MMS, who provided medical writing support funded by AstraZeneca.ClinicalTrials.gov identifier NCT00081380.This study was completed with the participation of the Trial 127 Study Investigators: Scott Aaronson, Sheppard Pratt Health Care System, Baltimore, Gustavo Alva, UCI Medical Center, Orange, Calif., Todd Antin, nTouch Research, Decatur, Ga., Valerie Arnold, Clinical NeuroScience, Memphis, Tenn., Roberta Ball, CNS Research Institute, Philadelphia, Benny Barnhart, Grayline Clinical Drug Trials, Wichita Falls, Kans., Jason Baron, MedLabs Research of Houston Inc., Houston, Bijan Bastani, North Coast Clinical Trials, Beachwood, Ohio, Louise Beckett, IPS Research Company, Oklahoma City, Ari Kiev, Social Psychiatry Research Institute, New York, Gary J. Booker, Shreveport, La., Guy E. Brannon, Brentwood Research Institute, Shreveport, La., Vicki Burdine, Valle Vista Health System, Greenwood, Ind., Jose M. Canive, New Mexico VA Health Care System, Albuquerque, John Carman, Carman Research, Smyrna, Ga., James C.-Y. Chou, Bellevue Hospital Center, New York, Andrew J. Cutler, CORE Research, Maitland, Fia., Bernadette D'Souza, Midwest Clinical Research Center, Dayton, Ohio, Brad Diner, Arkansas Psychiatric Clinic, Little Rock, Carlos Figueroa, Advanced Psychiatric Group, Pasadena, Calif., Donald J. Garcia, Jr., Futuresearch, Austin, Tex., Thomas Gazda, Meadowbrook Research, Scottsdale, Ariz., Ram Gopalan, Comprehensive Neuroscience of Northern Virginia, Arlington, James Grimm, Oregon Center for Clinical Investigations, Salem, Mahlon Hale, New Britain General Hospital, New Britain, Conn., Mark Hamner, Ralph H. Johnson VA Medical Center, Charleston, S. C., Linda Harper, Clinical NeuroScience Solutions, Orlando, FIa., Barbara Harris, PsyPharma Clinical Research, Phoenix, Howard Hassman, CNS Research Institute, Clementon, N.J., Naveed Iqbal, Soundview Throggs Neck Mental Health Center, New York, George Joseph, Clinical NeuroScience Solutions, Jacksonville, FIa., Jasbir Kang, CrossRoads Counseling and Consulting Associates, Moon Township, Pa., Zerrin Emel Kayatekin, Berkshire Medical Center, Pittsfield, Mass., Paul Keck, University of Cincinnati Medical Center, Cincinnati, Arifulla Khan, Northwest Clinical Research, Bellevue, Wash., Esha Khoshnu, Northern New Jersey Medical Institute, West Caldwell, Mary Ann Knesevich, University Hills Clinical Research, Irving, Tex., James Knutson, Eastside Therapeutic Resource, Kirkland, Wash., Mark Lerman, Comprehensive NeuroScience, Hoffman Estates, IM., Azfar Malik, Psych Care Consultants Research, St. Louis, David Marks, Optimum Health Services, La Mesa, Calif., Joseph McEvoy, John Umstead Hospital, Butner, N. C., Denis Mee-Lee, Hawaii Clinical Research Center, Honolulu, Charles Merideth, Affiliated Research Institute, San Diego, Alexander L. Miller, University of Texas Health Science Center at San Antonio, Janice L. Miller, Clinical Neuroscience Solutions, West Palm Beach, FIa., Raymond Manning, CNRI-LA, LLC, Pico Rivera, Calif., Rakesh Ranjan, Rakesh Ranjan and Associates, Inc., Medina, Ohio, Alfredo Rivera, Community Research, Cincinnati, Leon Rosenberg, Center for Emotional Fitness, Moorsetown, N.J., Leon Rubenfaer, Pioneer Pharmaceutical Research, New Baltimore, Mich., David Sack, Institute of Psychopharmacology Research, Cerritos, Calif., Mary C. Shemo, Psychiatric Alliance of the Blue Ridge. Charlottesville, Va., Raj Shiwach, The Cedars Hospital, DeSoto, Tex., James Stevenson, Addiction and Psychiatric Medicine Research, Morgantown, W.V., Tram TranJohnson, CNRI-San Diego, San Diego, Nicholas Vatakis, Social Psychiatry Research Institute, New York, David R Walling, CNS Network, Garden Grove, Calif., Richard Weisler, Richard Weisler M. D. and Associates, Raleigh, N.C., Trisha Suppes, UT Southwestern Medical Center at Dallas, Raj Rajani, Behavioral and Medical Research, Anaheim, Calif., H.E. Logue, Birmingham Psychiatry Pharmaceutical Studies, Birmingham, Ala., David E. Linden, Linden Research Consultants, Oklahoma City, David Miller, Friends Hospital, Philadelphia, Murray Rosenthal, Healthquest Clinical Trials, San Diego, Gene R. Flick, Medisphere Medical Research, Evansville, Ind., Norman E. Rosenthal, Capital Clinical Research Associates, Rockville, Md., Anantha Shekhar, Larue D. Carter Memorial Hospital, Indianapolis, Kashinath G. Yadalam, Lake Charles Clinical Trials, Lake Charles, La., Dwight St. Clair, Heartland Research Associates, Wichita, Kans., Georgia Jones, Medex Healthcare Research, St. Louis, John Duffy, APEX Research Institute, Santa Ana, Calif., John H. Gilliam, International Clinical Research Associales, Richmond, Va., Michael D. Banov, Northwest Behavioral Research Center, Manetta, Ga., Michael G. Dempsey, Albuquerque Neuroscience, Inc., Albuquerque, Mark D. Fossey, University of Oklahoma at Tulsa, Robert Levine, Neuropsych Research Associates, New York, Mohammed Abdul Bari, Synergy Research, National City, Calif., Robert A. Riesenberg, Atlanta Center for Medical Research, Atlanta, John M. Zajecka, Rush University Medical Center, Chicago, Richard W. Brown, Hartford Research Group, Cincinnati, David Feifel, San Diego Medical Center, San Diego, Richard L. Gibson, New Orleans Center for Clinical Research, New Orleans, Mark T. Schreiber, International Clinical Research Associates, Virginia Beach, Va., Valentin Isacescu, Optimum Health Services, Oceanside, Calif., Joachim Raese, Behavioral Health 2000, Riverside, Calif., Cosme Lozano, Jr., Center for Neuropsychiatrie Development, Joliet, III., Stephen M. Mohaupt, California Clinical Trials, Culver City, Alan H. Rosenbaum, Psychopharmacology Research Corporation, Farminton Hills, Mich., Franco Sicuro, Millennium Psychiatric Associates, St. Louis, Richard M. Steinbook, University of Miami/Department of Psychiatry, Miami, FIa., Peter Hauser, Portland VA Medical Center, Portland, Ore., Craig S, Risch, University of California, San Francisco, Andrew Winokur, University of Connecticut Health Center, Farmington, Cary J. Kohlenberg, Independent Psychiatric Consultants, Waukesha, Wise.,;
机译:患有双相I障碍患者的维持治疗:一项基于喹硫平与锂或双丙戊酸钠合用的北美研究结果(试验127)。
机译:喹硫平与锂或双丙戊酸钠联合治疗双相性I型障碍患者的疗效和安全性(国际试验126)。
机译:双峰I疾病中锂与双丙戊酸钠合用时用喹硫平进行保养治疗:两种随机对照试验的分析
机译:预防双极I紊乱中的复发:喹硫代单药治疗的比较研究与喹硫氨酸 - 戊醛组合治疗
机译:躁郁症患者团体认知行为治疗的随机对照试验:对社会功能和生活质量的影响。
机译:锂单药治疗为期6个月的双盲维护试验与锂和Divalproex的组合用于快速循环双相情感障碍和同时发生的药物滥用或依赖
机译:槲皮素与锂或双丙戊酸合用的PMH30成本效益:在双歧I疾病的维持治疗中